TAMPA, Fla., Dec. 01, 2016 -- After a week-long arbitration before a panel of three arbitrators, a local physician received a $1,500,000.00 award against healthcare giant OptumRx, a pharmacy benefits management company associated with United Healthcare. The award, which also required OptumRx to pay all costs associated with the litigation, included a finding that family medicine physician Jose I. Lopez, M.D. was entitled to punitive damages in the amount of $1,000,000.00 due to OptumRx’s “intentional misconduct or gross negligence” that was “condoned, ratified or consented to” by Optum’s officers, directors or managers.
Dr. Lopez was represented by Jody M. Valdes and Paul M. Weekley of Weekley Schulte Valdes in Tampa.
“More strikingly, however, the Panel of Arbitrators determined that OptumRx, Inc.’s wrongful conduct was ‘motivated solely by unreasonable financial gain and the unreasonably dangerous nature of the conduct, together with the high likelihood of injury resulting from the conduct, was actually known by the managing agent, director, officer, or other person responsible for making policy decisions,’” said Valdes.
“The case arose after OptumRx publicly and repeatedly made false statements about Dr. Lopez, wrongly labeling him as a physician-sanctioned by the Office of Inspector General. In actuality, OptumRx had misidentified Dr. Lopez. The Jose Lopez who was sanctioned by OIG lived in another city in Florida and was not even a physician. The Panel of Arbitrators concluded that OptumRx injured Dr. Lopez’s reputation in the community by falsely advising pharmacies, Dr. Lopez’s patients, and others that Dr. Lopez was a sanctioned provider. OptumRx failed to acknowledge the mistake and continued making the false statements despite repeated attempts by Dr. Lopez to get OptumRx to investigate whether OptumRx had identified another person with a similar name,” stated Weekley.
“We believe that this is the first case of its kind, in which a pharmacy benefits manager has been held accountable for poor procedures that resulted in a physician being wrongfully defamed,” stated Valdes. “During the litigation process, we learned that Dr. Lopez was one of many physicians who was defamed by similar misconduct or gross negligence,” added Weekley.
The Panel concluded that the “clear and unmistakable import of the false statements was that Claimants had engaged in some improper conduct sufficient to merit a “penalty, punitive or disciplinary action,” which is a definition of 'sanctioned',” said Valdes.
The Panel further noted that the “statements conveyed the false notion that Claimants had committed some offense in the medical profession sufficient to be disciplined and excluded as a Medicare provider – only leaving to the audience’s imagination which bad act, whether it be fraud, malpractice, etc., led to the punishment.” In reality, Dr. Lopez has always been in good standing with the state licensing agency, and with Medicare,” stated Weekley.
“The Panel determined that the evidence established to a clear and convincing standard that OptumRx, Inc. was aware of a problem with physicians being improperly listed as “sanctioned” and was specifically aware of this problem with Dr. Lopez. However, OptumRx, Inc. was unwilling to “take the few hours necessary to correct the information before publishing the information and did not engage in any efforts to correct its…continual misidentification,” said Valdes.
Dr. Lopez was pleased with the decision and commented that “this case was not about money. This case about sending a strong and clear message that faceless companies that libel and slander doctors must be held accountable for their actions.”
Eric W. Rose with Englander Knabe & Allen testified as an expert witness and addressed the effects of disseminating the false information and the impact on the doctor’s professional reputation. Rose also testified about the appropriate standard of care that should have taken place and outlined steps Dr. Lopez should take to recover his good professional reputation.
Contact: Paul M. Weekley, Esquire (813) 221-1154 or [email protected]


SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Apple Turns 50: From Garage Startup to AI Crossroads
Britain Courts Anthropic Amid US Defense Department Dispute
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 



